Media Center

Events

2023
  • - June 2-6. 2023 ASCO Annual Meeting. Chicago.
  • - May 16-18. BIOMED Israel. The 21st National Life Sciece & Technology Week. Tel Aviv.
2022
  • - November - LSX Investival showcase. London
  • - October - SACHS Forum. Digital.
  • - June - BIO 2022. San Diego. In person
  • - April - ASEBIO Investors Day. In person
  • - March - BioEurope Spring. Digital.
  • - March - Biomed Event. Paris.
  • - February - SACHS Forum. Digital.
2021
  • September - BioSpain. Pamplona
  • May - Anglonordic. Digital
  • May - BioEquity. Digital
  • March - BIO-Europe Spring. Digital
  • February - LSX World Congress. Digital
2020
  • March - BIO-Europe Spring. Paris (France)
  • February - 15th Biomarkers Series UK. Manchester (United Kingdom) - Marc Yeste, PhD: Pharmacodynamic biomarkers associated to ABTL0812, a phase 2 clinical stage pro-autophagy anticancer drug
  • January - J. P. Morgan (USA)
2019
  • November - BIO-Europe. Hamburg (Germany)
  • September - ESMO: European Society for Medical Oncology. Barcelona
  • June - BIO International. Philadelphia (USA)
  • June - ASCO Annual Meeting. Chicago (USA)
  • May - MIXiii-Biomed 2019. Tel Aviv (Israel)
  • January - Invest Securities BioMed Event
  • January - 2019 Cholangiocarcinoma Foundation Annual Conference. Salt Lake City (USA)
2018
  • October - Pau Muñoz will defend the Doctoral thesis: "Mechanism of action of the new antitumour drug ABTL0812: Role of pseudoquinase TRIB3, reticular stress and sphingolipids in death mediated by autophagy". UAB (Bellaterra, Barcelona)
  • October - Sachs Forum. Basel (Switzerland)
  • September - BioSpain. Sevilla (Spain)
  • June - ASCO Annual Meeting. Chicago, IL (USA)
  • June - II Biennal Congress of the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Rome (Italy)
  • May - Bio€quity Europe. Ghent (Belgum)
2017
  • November - BioEurope. Berlin (Germany)
  • October - CPhI Worldwide. Frankfurt (Germany)
  • September - ASEBIO Investors Day. Barcelona (Catalnoia)
  • September - Sachs Forum. Basel (Switzerland)
  • June - 2017 BIO International Convention. San Diego, CA (USA)
  • June - ASCO Annual Meeting. Chicago, IL (USA)
  • March - BioEurope. Barcelona (Catalonia - Spain)
  • March - 10th Annual European Life Sciences CEO Forum & Exhibition. Zurich (Switzerland)
2016
  • October - BioEurope. Cologne (Germany)
  • October - CPhI. Barcelona (Catalonia, Spain)
  • June - BIO international convention. San Francisco, CA (USA)
  • September - BioSpain. Bilbao (Spain)
  • September - BioJapan (Japan)
2015
  • November - AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, MA (USA)
  • September - ESMO: European Society for Medical Oncology. Vienna (Austria)
  • May - IATI Biomed. Tel Aviv (Israel)
  • May - Biotrinity. London (UK)
  • April - Anglonordic Life Science Conference. (Spain)
  • February - BIO CEO & Investor Conference. New York, NY (USA)
2013
  • April - BIO International Convention. Chicago, IL (USA)
  • March - BioEurope Spring. Barcelona (Catalonia, Spain)
  • March - Company presentation at 6th Annual European Life Science CEO Forum for Partnering & Investing. Zurich (Switzerland)
  • January - Company presentation at Biotech Showcase at JP Morgan Healthcare Conference. San Francisco, CA (USA)
2012
  • September - Poster session at the 8th International Translational Oncology Symposium. Barcelona
  • July - Poster session at the meeting of the European Association for Cancer Research (EACR). Barcelona (Catalonia, Spain)
  • June - Booth at BIO International Convention. Boston, MA (USA)
  • June - Company presentation at the International Cancer Cluster Showcase. Boston, MA (USA)
  • April - Poster session at the meeting of the American Association for Cancer Research (AACR). Chicago, IL (USA)
  • March - Company presentation at 5th Annual European Life Science CEO Forum for Partnering & Investing. Zurich (Switzerland)
2011
  • November - Company presentation at NYC Landmark Venture Forum - Investing for Cures. New York, NY (USA)
  • November - Company presentation at Foro Neotec (CDTI). Logrono (Spain)
  • September - Company presentation at MassBio’s Global Gateway. Boston, MA (USA)
  • September - Company presentation at BioPharm America. Boston, MA (USA)
  • May - Company presentation at Oncology Forum Farmaindustria. Madrid (Spain)
  • June - BIO International Convention. Washington, DC (USA)
  • May - 7th International Translational Oncology Symposium. Barcelona (Catalonia, Spain)
  • April - BioTrinity. Newbury (United Kingdom)
  • January - Company presentation at 4th Annual European Life Science CEO Forum for Partnering & Investing. Zurich (Switzerland)
2010
  • November - BioEurope. Munich (Germany)
  • November - Company presentation at European Venture Capital Contest Summit. Düsseldorf (Germany)
  • October - Company presentation at European Venture Capital Contest Semi-Final. Pamplona (Spain)
  • September - Company presentation at BioSpain. Pamplona (Spain)
  • August - Company presentation at European Venture Capital Contest Semi-Final. Aarhus (Denmark)
  • June - HiT Barcelona World Innovation Summit. Barcelona (Catalonia, Spain)
  • March - BioEurope Spring. Barcelona (Catalonia, Spain)

LATEST NEWS

11.03.2024

Press Release

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023

Press Release

Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022

Press Release

AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022

Press Release

AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022

Press Release

AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
02.11.2022

Press Release

ABTL0812 shows potential against glioblastoma brain tumors + info
07.10.2022

Press Release

AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812 + info
07.09.2022

Press Release

Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer + info
29.06.2022

Press Release

AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG